Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
Open Access
- 31 August 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 34 (1) , 92-102
Abstract
Cancer patients often suffer from cancer symptoms, treatment complications and concomitant diseases and are, therefore, often treated with several drugs in addition to anticancer drugs. Whether such drugs, here denoted as ‘concomitant drugs’, have anticancer effects or interact at the tumor cell level with the anticancer drugs is not very well known. The cytotoxic effects of nine concomitant drugs and their interactions with five anti-cancer drugs commonly used for the treatment of colorectal cancer were screened over broad ranges of drug concentrations in vitro in the human colon cancer cell line HCT116wt. Seven additional tyrosine kinase inhibitors were included to further evaluate key findings as were primary cultures of tumor cells from patients with colorectal cancer. Cytotoxic effects were evaluated using the fluorometric microculture cytotoxicity assay (FMCA) and interaction analysis was based on Bliss independent interaction analysis. Simvastatin and loperamide, included here as an opioid agonists, were found to have cytotoxic effects on their own at reasonably low concentrations whereas betamethasone, enalapril, ibuprofen, metformin, metoclopramide, metoprolol and paracetamol were inactive also at very high concentrations. Drug interactions ranged from antagonistic to synergistic over the concentrations tested with a more homogenous pattern of synergy between simvastatin and protein kinase inhibitors in HCT116wt cells. Commonly used concomitant drugs are mostly neither expected to have anticancer effects nor to interact significantly with anticancer drugs frequently used for the treatment of colorectal cancer.Keywords
This publication has 38 references indexed in Scilit:
- A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically RelevantIn VitroMulticompound AnalysesMolecular Cancer Therapeutics, 2014
- Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximabInvestigational New Drugs, 2014
- Cytotoxic Effects of Loperamide Hydrochloride on Canine Cancer CellsJournal of Veterinary Medical Science, 2014
- Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patientsCancer Chemotherapy and Pharmacology, 2013
- Simvastatin reduces melanoma progression in a murine modelInternational Journal of Oncology, 2013
- Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathwayCancer Letters, 2013
- Loperamide, an antidiarrhea drug, has antitumor activity by inducing cell apoptosisPharmacological Research, 2012
- Loperamide, an FDA-Approved Antidiarrhea Drug, Effectively Reverses the Resistance of Multidrug Resistant MCF-7/MDR1 Human Breast Cancer Cells to Doxorubicin-Induced CytotoxicityCancer Investigation, 2012
- A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2011
- The fluorometric microculture cytotoxicity assayNature Protocols, 2008